Danijela Mrazovac Zimak

Dr. Danijela Mrazovac Zimak

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2022 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
PDF file
Snježana KaštelanSnježana Kaštelan
Snježana Kaštelan
DZDanijela Mrazovac Zimak
Danijela Mrazovac Zimak
MIMira Ivanković
Mira Ivanković
IMIrena Marković
Irena Marković
AAAntonela Gverović Antunica
Antonela Gverović Antunica
Uveal melanoma (UM) is the most prevalent primary intraocular malignancy in adults with a stable incidence rate between five and seven cases per million in Europe and the United States. Although UM and melanoma from other sites have the same origin, UM has different epidemiological, biological, pathological and clinical features including characteristic metastatic hepatotropism. Despite improvements in the treatment of primary tumours, approximately 50% of patients with UM will develop metastases. In 90% of cases the liver is the first site of metastasis, however the mechanisms underlying this hepatic tropism have not been elucidated. Metastatic disease is associated with a very poor prognosis with a median overall survival of 6 to 12 months. Currently, there is no standard systemic treatment available for metastatic UM and once liver metastases have developed, prognosis is relatively poor. In order to prolong survival, close follow-up in all patients with UM is recommended for early detection and treatment. The treatment of metastatic UM includes systemic chemotherapy, immunotherapy and molecular targeted therapy. Liver-directed therapies, such as resection, radioembolization, chemoembolization, immunoembolization, isolated and percutaneous liver perfusion as well as thermal ablation represent available treatment options. However, to date a consensus regarding the optimal method of treatment is still lacking and the importance of setting guidelines in the treatment and management of metastatic UM is becoming a priority. Improvement in knowledge and a better insight into tumour biology, immunology and metastatic mechanism may improve current treatment methods and lead to the development of new strategies paving the way for a personalized approach.

14 January 2018 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
JMjelena juri mandić
jelena juri mandić
AKAna Kozmar
Ana Kozmar
SKSanja Kusačić-Kuna
Sanja Kusačić-Kuna
AJAnamarija Jazbec
Anamarija Jazbec
KMKrešimir Mandić
Krešimir Mandić
NVNenad Vukojević
Nenad Vukojević

14 May 2012 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
MMMaja Mustapic
Maja Mustapic
MHMarijana Popovic Hadzija
Marijana Popovic Hadzija
MPMladen Pavlovic
Mladen Pavlovic
PPPajica Pavkovic
Pajica Pavkovic
PPPaola Presecki
Paola Presecki
DMDorotea Muck-Seler
Dorotea Muck-Seler

24 May 2017 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
JMjelena juri mandić
jelena juri mandić
KMKrešimir Mandić
Krešimir Mandić
DZDanijela Mrazovac Zimak
Danijela Mrazovac Zimak
Purpose: To present our experience in the management of superior ophthalmic vein thrombosis (SOVT), which is a rare, but extremely serious condition if not recognized and managed promptly and appropriately. Methods: Two patients with septic and aseptic SOVT are presented. Clinical characteristics, radiographic features, management techniques, and outcomes are described. Results: In the first case thrombosis occurred as a complication of functional endoscopic sinus surgery. In the second case thrombosis occurred as a complication of untreated inflammatory bowel disease: ulcerative colitis. Both cases resulted with permanent unilateral blindness. Conclusion: SOVT is a rare entity. There are no guidelines, just recommendations for disease management. Based on our experience, broad-spectrum intravenous antibiotic, anticoagulation, and steroid therapy should be promptly introduced and if needed surgical intervention. SOVT can lead to devastating complications which include permanent loss of vision and in some cases a fatal outcome.

4 August 2025 in Pathology and Oncology Research
Verified
Journal Article
Open access
PDF file
Snježana KaštelanSnježana Kaštelan
Snježana Kaštelan
DZDanijela Mrazovac Zimak
Danijela Mrazovac Zimak
LILuka Ivić
Luka Ivić
AAAntonela Gverović Antunica
Antonela Gverović Antunica
TNTamara Nikuševa-Martić
Tamara Nikuševa-Martić
Conjunctival melanoma (CoM) is a rare and aggressive ocular surface malignancy, characterised by increasing incidence, clinical complexity, and substantial challenges in diagnosis and treatment. This review consolidates current knowledge on epidemiology, clinical presentation, genetic and epigenetic foundations, molecular mechanisms, emerging therapeutic strategies, and prognostic factors for localised and metastatic CoM. CoM exhibits distinct biological behaviours, sharing molecular traits with cutaneous and mucosal melanomas, while significantly diverging from uveal melanoma. Key genetic alterations include mutations in BRAF, NF1, and PTEN, elevated mTOR expression, and specific miRNA profiles, which influence tumour progression and response to therapy. Recent advances in treatment, especially immune checkpoint inhibitors such as CTLA-4 and PD-1 receptor inhibitors, along with targeted therapies like BRAF and MEK inhibitors, have led to marked improvements in outcomes for advanced cases. Emerging strategies, including dendritic cell vaccines and epigenetic therapies, hold considerable promise in addressing ongoing clinical challenges. This review integrates case studies and clinical research to demonstrate the practical application of these therapies, highlighting their efficacy and limitations. Combining clinical expertise, genetic insights, and the latest therapeutic developments, offers a comprehensive overview of CoM, underscoring the critical role of a multidisciplinary approach in optimising diagnosis, management, and prognosis to improve patient outcomes.

Verified
Journal Article
Open access
PDF file
Snježana KaštelanSnježana Kaštelan
Snježana Kaštelan
TNTamara Nikuševa-Martić
Tamara Nikuševa-Martić
DPDaria Pašalić
Daria Pašalić
AAAntonela Gverović Antunica
Antonela Gverović Antunica
DZDanijela Mrazovac Zimak
Danijela Mrazovac Zimak
Alzheimer’s disease (AD) represents a prominent neurodegenerative disorder (NDD), accounting for the majority of dementia cases worldwide. In addition to memory deficits, individuals with AD also experience alterations in the visual system. As the retina is an extension of the central nervous system (CNS), the loss in retinal ganglion cells manifests clinically as decreased visual acuity, narrowed visual field, and reduced contrast sensitivity. Among the extensively studied retinal disorders, age-related macular degeneration (AMD) shares numerous aging processes and risk factors with NDDs such as cognitive impairment that occurs in AD. Histopathological investigations have revealed similarities in pathological deposits found in the retina and brain of patients with AD and AMD. Cellular aging processes demonstrate similar associations with organelles and signaling pathways in retinal and brain tissues. Despite these similarities, there are distinct genetic backgrounds underlying these diseases. This review comprehensively explores the genetic similarities and differences between AMD and AD. The purpose of this review is to discuss the parallels and differences between AMD and AD in terms of pathophysiology, genetics, and epigenetics.